Premium
Overview of the use of CoQ 10 in cardiovascular disease
Author(s) -
Langsjoen Peter H.,
Langsjoen Alena M.
Publication year - 1999
Publication title -
biofactors
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.204
H-Index - 94
eISSN - 1872-8081
pISSN - 0951-6433
DOI - 10.1002/biof.5520090224
Subject(s) - medicine , cardiology , ventricle , heart failure , coronary artery disease , disease , cardiovascular health , adverse effect
The clinical experience in cardiology with CoQ 10 includes studies on congestive heart failure, ischemic heart disease, hypertensive heart disease, diastolic dysfunction of the left ventricle, and reperfusion injury as it relates to coronary artery bypass graft surgery. The CoQ 10 ‐lowering effect of HMG‐CoA reductase inhibitors and the potential adverse consequences are of growing concern. Supplemental CoQ 10 alters the natural history of cardiovascular illnesses and has the potential for prevention of cardiovascular disease through the inhibition of LDL cholesterol oxidation and by the maintenance of optimal cellular and mitochondrial function throughout the ravages of time and internal and external stresses. The attainment of higher blood levels of CoQ 10 (>3.5 μg/ml) with the use of higher doses of CoQ 10 appears to enhance both the magnitude and rate of clinical improvement. In this communication, 34 controlled trials and several open‐label and long‐term studies on the clinical effects of CoQ 10 in cardiovascular diseases are reviewed.